In the latest session, Exact Sciences Corp. (NASDAQ: EXAS) closed at $56.31 down -1.04% from its previous closing price of $56.90. In other words, the price has decreased by -$0.59 from its previous closing price. On the day, 1627849 shares were traded. EXAS stock price reached its highest trading level at $57.42 during the session, while it also had its lowest trading level at $56.05.
Ratios:
For a deeper understanding of Exact Sciences Corp.’s stock, let’s take a closer look at its various ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 13.14 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 320.14. For the most recent quarter (mrq), Quick Ratio is recorded 2.07 and its Current Ratio is at 2.32. In the meantime, Its Debt-to-Equity ratio is 0.82 whereas as Long-Term Debt/Eq ratio is at 0.79.
On December 14, 2023, Guggenheim started tracking the stock assigning a Buy rating and target price of $90.
On December 13, 2023, Wolfe Research started tracking the stock assigning a Outperform rating and target price of $95.Wolfe Research initiated its Outperform rating on December 13, 2023, with a $95 target price.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Feb 27 when Conroy Kevin T sold 6,263 shares for $56.89 per share. The transaction valued at 356,302 led to the insider holds 1,289,624 shares of the business.
Cunningham Everett sold 3,648 shares of EXAS for $207,535 on Feb 27. The Chief Commercial Officer now owns 43,300 shares after completing the transaction at $56.89 per share. On Feb 27, another insider, Elliott Jeffrey Thomas, who serves as the Chief Financial Officer of the company, sold 2,710 shares for $56.89 each. As a result, the insider received 154,172 and left with 8,054 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, EXAS now has a Market Capitalization of 10.22B and an Enterprise Value of 12.00B. For the stock, the TTM Price-to-Sale (P/S) ratio is 4.09 while its Price-to-Book (P/B) ratio in mrq is 3.25. Its current Enterprise Value per Revenue stands at 4.80 whereas that against EBITDA is 409.76.
Stock Price History:
Over the past 52 weeks, EXAS has reached a high of $100.77, while it has fallen to a 52-week low of $56.11. The 50-Day Moving Average of the stock is 65.99, while the 200-Day Moving Average is calculated to be 75.20.
Shares Statistics:
For the past three months, EXAS has traded an average of 1.90M shares per day and 2.6M over the past ten days. A total of 181.36M shares are outstanding, with a floating share count of 179.73M. Insiders hold about 0.99% of the company’s shares, while institutions hold 89.92% stake in the company. Shares short for EXAS as of Feb 15, 2024 were 7.27M with a Short Ratio of 3.83, compared to 7.6M on Jan 12, 2024. Therefore, it implies a Short% of Shares Outstanding of 4.01% and a Short% of Float of 4.05%.
Earnings Estimates
There are 16 different market analysts currently analyzing its stock. On average, analysts expect EPS of -$0.46 for the current quarter, with a high estimate of -$0.17 and a low estimate of -$0.63, while EPS last year was -$0.42. The consensus estimate for the next quarter is -$0.23, with high estimates of -$0.09 and low estimates of -$0.33.
Analysts are recommending an EPS of between -$0.31 and -$1.29 for the fiscal current year, implying an average EPS of -$0.85. EPS for the following year is $0.01, with 18 analysts recommending between $0.81 and -$0.64.
Revenue Estimates
A total of 20 analysts believe the company’s revenue will be $630.32M this quarter.It ranges from a high estimate of $682M to a low estimate of $619.99M. As of the current estimate, Exact Sciences Corp.’s year-ago sales were $602.45M, an estimated increase of 4.60% from the year-ago figure. For the next quarter, 20 analysts are estimating revenue of $700.87M, an increase of 12.70% over than the figure of $4.60% in the same quarter last year. There is a high estimate of $721.08M for the next quarter, whereas the lowest estimate is $687.31M.
A total of 23 analysts have provided revenue estimates for EXAS’s current fiscal year. The highest revenue estimate was $2.87B, while the lowest revenue estimate was $2.82B, resulting in an average revenue estimate of $2.83B. In the same quarter a year ago, actual revenue was $2.5B, up 13.40% from the average estimate. Based on 22 analysts’ estimates, the company’s revenue will be $3.23B in the next fiscal year. The high estimate is $3.3B and the low estimate is $3.17B. The average revenue growth estimate for next year is up 13.90% from the average revenue estimate for this year.
